Perinatal Management and Clinical Outcomes of Hereditary Angioedema in Japan: A Case Series and Comprehensive
Kanade Iino1, Saori Takamura1, Tomoo Fukuda1
1Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by C1-inhibitor (C1-INH) deficiency or dysfunction, leading to recurrent, nonpruritic edema of the skin, gastrointestinal tract, and airways. Estrogen fluctuations during pregnancy can exacerbate attacks; however, standardized perinatal management protocols remain underdeveloped in Japan. We report two cases of vaginal delivery in type I HAE and review 14 Japanese reports encompassing 19 pregnancies to clarify clinical characteristics, maternal-fetal outcomes, and evolving treatment strategies. Case 1 involved a primigravida with a marked increase in abdominal attacks during pregnancy (23 episodes), all treated with plasma-derived C1-INH (pdC1-INH). Short-term prophylaxis (STP) was administered before forceps-assisted delivery, which was completed without an attack; however, she experienced weekly postpartum attacks. Case 2, diagnosed via family screening, underwent three vaginal deliveries-one with forceps-over 7 years. Long-term prophylaxis was available in later pregnancies but not initiated due to low attack frequency and patient preference. STP with pdC1-INH was given at all deliveries, with only one mild lip swelling 3 years after the first birth and no postpartum attacks after the latter two. Among 17 Japanese pregnancies with available data, 9 (52.9%) showed increased attack frequency during gestation, particularly in early and late trimesters. Since 2013, STP at delivery-regardless of mode-was performed in 12 of 15 documented cases (80.0%). Postpartum attacks occurred in 6 of 16 cases (37.5%), warranting close monitoring. In Japan, since 2017, pdC1-INH has been the only approved agent for STP at delivery, recommended in guidelines for its proven safety and efficacy. Our findings support individualized, multidisciplinary perinatal care, with STP using pdC1-INH as a cornerstone for enhancing maternal safety and providing substantial psychological reassurance.
Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by C1-inhibitor (C1-INH) deficiency or dysfunction, leading to recurrent, nonpruritic edema of the skin, gastrointestinal tract, and airways. Estrogen fluctuations during pregnancy can exacerbate attacks; however, standardized perinatal management protocols remain underdeveloped in Japan. We report two cases of vaginal delivery in type I HAE and review 14 Japanese reports encompassing 19 pregnancies to clarify clinical characteristics, maternal-fetal outcomes, and evolving treatment strategies. Case 1 involved a primigravida with a marked increase in abdominal attacks during pregnancy (23 episodes), all treated with plasma-derived C1-INH (pdC1-INH). Short-term prophylaxis (STP) was administered before forceps-assisted delivery, which was completed without an attack; however, she experienced weekly postpartum attacks. Case 2, diagnosed via family screening, underwent three vaginal deliveries-one with forceps-over 7 years. Long-term prophylaxis was available in later pregnancies but not initiated due to low attack frequency and patient preference. STP with pdC1-INH was given at all deliveries, with only one mild lip swelling 3 years after the first birth and no postpartum attacks after the latter two. Among 17 Japanese pregnancies with available data, 9 (52.9%) showed increased attack frequency during gestation, particularly in early and late trimesters. Since 2013, STP at delivery-regardless of mode-was performed in 12 of 15 documented cases (80.0%). Postpartum attacks occurred in 6 of 16 cases (37.5%), warranting close monitoring. In Japan, since 2017, pdC1-INH has been the only approved agent for STP at delivery, recommended in guidelines for its proven safety and efficacy. Our findings support individualized, multidisciplinary perinatal care, with STP using pdC1-INH as a cornerstone for enhancing maternal safety and providing substantial psychological reassurance.
Related Concept Videos
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:21Rheumatic Heart Disease III: Medical Management
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies